0000000000142657

AUTHOR

Stefan Störk

0000-0002-1771-7249

showing 4 related works from this author

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European…

2016

AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% female…

EUROASPIRE InvestigatorsMaleCardiac & Cardiovascular SystemsTime FactorsEpidemiologyCARDIOVASCULAR-DISEASE PREVENTIONCoronary DiseaseComorbidity030204 cardiovascular system & hematologyOverweightlaw.invention0302 clinical medicineRandomized controlled triallawRisk FactorsPrevalenceSecondary PreventionARTERY-DISEASE030212 general & internal medicineEUROASPIREguidelinesProspective StudiesPractice Patterns Physicians'Societies MedicalSecondary preventionGLUCOSE REGULATIONSmokingcardiovascular preventionRANDOMIZED CONTROLLED-TRIALMiddle AgedClinical PracticeEuropeTreatment OutcomePractice Guidelines as TopicCardiologyLDL Cholesterol LipoproteinsFemaleGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentCardiologyHEART-DISEASERisk Assessmentrehabilitation03 medical and health sciencesYoung AdultCardiovascular preventionSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansRisk factorCARDIAC REHABILITATIONExerciseAgedScience & TechnologyTask forcebusiness.industryCardiovascular AgentsDietCross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEHealth Care SurveysCardiovascular System & CardiologySmoking CessationSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCEEuropean journal of preventive cardiology
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (&amp;gt;40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct

Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized c…

2019

Abstract Aims Anxiety, depression, and reduced quality of life (QoL) are common in patients with implantable cardioverter-defibrillators (ICDs). Treatment options are limited and insufficiently defined. We evaluated the efficacy of a web-based intervention (WBI) vs. usual care (UC) for improving psychosocial well-being in ICD patients with elevated psychosocial distress. Methods and results This multicentre, randomized controlled trial (RCT) enrolled 118 ICD patients with increased anxiety or depression [≥6 points on either subscale of the Hospital Anxiety and Depression Scale (HADS)] or reduced QoL [≤16 points on the Satisfaction with Life Scale (SWLS)] from seven German sites (mean age 58…

Malemedicine.medical_specialtyPsychological interventionMixed anxiety-depressive disorderAnxiety030204 cardiovascular system & hematologyHospital Anxiety and Depression Scalelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawmedicineHumansAgedCognitive Behavioral TherapyDepressionbusiness.industry030229 sport sciencesMiddle Agedmedicine.diseaseDefibrillators ImplantableDistressQuality of LifePhysical therapyAnxietyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessPsychosocialInternet-Based InterventionEuropean Heart Journal
researchProduct